Market Research Logo

PharmaFocus: Supportive Care in Oncology

PharmaFocus: Supportive Care in Oncology

Summary

Supportive care in oncology is a broad term that is composed of indications that are either a symptom of a patient’s cancer or a side effect of cancer treatment. This report focuses on six prominent cancer supportive care indications: chemotherapy-induced nausea and vomiting (CINV), cancer cachexia, oral mucositis, bone metastases, chemotherapy-induced neutropenia (CIN), and chemotherapy-induced anemia (CIA).

There is a consensus among KOLs across the 7MM that supportive oncology had not been given much priority by physicians and institutions in the past. However, there is also a consensus that this situation has been improving in recent years, with increasing recognition of the importance of supportive care.

A growing library of evidence indicates that supportive care: increases likelihood of completing treatment, without the need for dose reductions or treatment pauses; can reduce costs for healthcare institutions; and can improve quality of life for patients-all of which will become increasingly important as patients continue to live longer and cancer progresses to become more like a chronic disease. Despite the trends in oncology towards targeted therapies, KOLs agree that chemotherapy will remain the backbone of cancer treatment for the next five to 10 years. Thus, as the incidence of cancer rises over the next 10 years, so will the cases of chemotherapy-related conditions, in addition to a rise in general oncology-related conditions.

Scope

  • Highlight KOL views on the past, present, and future trends in supportive care in oncology in their countries
  • Provide cancer and cancer supportive care epidemiological insight
  • Provide an overview of the market landscape and available therapies
  • Provide an overview of all late-stage (Phase II and III) candidates and evaluate the prominent pipeline agents that are closest to market entry
  • Identify the unmet needs and opportunities in each indication
  • Highlight R&D strategies used by developers in this field, alongside clinical trial design considerations and challenges
  • Provide detailed key opinion leader insight throughout each indication and aspect of this report.
Reasons to buy

The report will enable you to -
  • Develop business strategies by understanding the trends shaping and driving the global supportive care in oncology market
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global supportive care market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

  • 1 Table of Contents
    1.1 List of Tables
    1.2 List of Figures
    2 Executive Summary
    2.1 Traditionally Overlooked Field, but Recognition of Supportive Oncology is Growing Across the 7MM, and will Continue to do so in the Next Five to Ten Years.
    2.2 Marketed Landscape Varies Significantly - Blockbuster Drugs in CIN, CIA, and Bone Metastases, but Nothing Available for Cancer Cachexia
    2.3 CIN and Oral Mucositis Possess the Largest Late Stage (Phase II and III) Pipelines
    2.4 Unmet Needs Remain in Each Indication, Primarily in Cancer Cachexia and Oral Mucositis, Given the Lack of Effective Therapies
    2.5 R&D and Clinical Trial Design in Supportive Oncology Presents Unique Challenges
    2.6 What Do Physicians Think?
    3 Introduction
    3.1 Objectives
    3.2 Related Reports
    4 Supportive Care in Oncology Global Landscape: KOL Views
    4.1 Overview
    4.2 US Supportive Care Landscape
    4.2.1 Current Status of Supportive Care in Oncology
    4.2.2 Physician and Patient Attitudes Towards Supportive Care in Oncology
    4.2.3 Future Trends
    4.3 UK Supportive Care Landscape
    4.3.1 Current Status of Supportive Oncology and Physician/Patient Attitudes towards Supportive Oncology
    4.3.2 Future Trends
    4.4 Germany Supportive Care Landscape
    4.4.1 Current Status of Supportive Oncology and Physician/Patient Attitudes towards Supportive Oncology
    4.4.2 Future Trends
    4.5 Spain Supportive Care Landscape
    4.6 Japan Supportive Care Landscape
    4.6.1 Who Provides Supportive Care in Japan
    4.6.2 Current State of Supportive Oncology in Japan
    4.6.3 Future Trends
    4.7 Guidelines Followed by KOLs
    4.7.1 Chemotherapy Induced Nausea and Vomiting
    4.7.2 Chemotherapy-Induced Neutropenia
    5 Epidemiology
    5.1 Cancer Background, Global and Historic Trends
    5.2 Methodology and Sources
    5.2.1 Assumptions and Methods
    5.3 Epidemiology for Supportive Care in Oncology (2016-2026)
    5.3.1 Diagnosed Incident Cases of All Cancer
    5.3.2 Diagnosed Incident Cases of All Cancer Receiving Chemotherapy Treatment
    5.3.3 Diagnosed Incident Cases of Chemotherapy-Induced Conditions
    5.3.4 Diagnosed Incident Cases of Prostate Cancer
    5.3.5 Diagnosed Incident Cases of Prostate Cancer That Develop Bone Metastasis
    5.3.6 Diagnosed Incident Cases of Breast Cancer
    5.3.7 Diagnosed Incident Cases of Breast Cancer That Develop Bone Metastasis
    5.3.8 Diagnosed Incident Cases of Lung Cancer
    5.3.9 Diagnosed Incident Cases of Lung Cancer that Develop Bone Metastasis
    5.3.10 Five-Year Diagnosed Prevalent Cases of All Cancer
    5.4 Discussion, Limitations and Strengths of Analysis
    6 Marketed Products
    6.1 Chemotherapy-Induced Nausea and Vomiting
    6.1.1 Emend and Emend for Injection
    6.1.2 Varubi and Varubi IV
    6.1.3 Aloxi
    6.1.4 Sustol
    6.1.5 Akynzeo
    6.1.6 Syndros and Marinol
    6.1.7 Olanzapine - Off-Label Use
    6.2 Cancer Cachexia
    6.3 Oral Mucositis
    6.3.1 Kepivance
    6.3.2 Mucosta (Off-Label) and Gels for Oral Mucositis
    6.4 Bone Metastases
    6.4.1 Xgeva
    6.4.2 Xofigo
    6.4.3 Zometa and Aredia
    6.5 Chemotherapy-Induced Neutropenia
    6.5.1 Neupogen
    6.5.2 Filgrastim Biosimilars
    6.5.3 Granix and Granocyte
    6.5.4 Neulasta
    6.5.5 Lonquex and Leukine
    6.6 Chemotherapy Induced Anemia
    6.6.1 Procrit/Eprex/Epogen
    6.6.2 Epoetin Alfa Biosimilars, NeoRecormon, and Eporatio / Biopoin
    6.6.3 Aranesp
    7 Pipeline Assessment
    7.1 Chemotherapy-Induced Nausea and Vomiting
    7.1.1 CINV Phase II and III Pipeline
    7.1.2 APD403 (Amisulpride) - Acacia Pharma
    7.1.3 Cinvanti (Aprepitant/HTX-019) - Heron Therapeutics
    7.2 Cancer Cachexia
    7.2.1 Cancer Cachexia Phase II and III Pipeline Overview
    7.2.2 Adlumiz (Anamorelin) - Helsinn
    7.2.3 Xilonix (MABp1) - XBiotech
    7.3 Oral Mucositis
    7.3.1 Oral Mucositis Phase II and III Pipeline Overview
    7.3.2 SGX942 (Dusquetide) - Soligenix Inc.
    7.3.3 Validive (Clonidine Lauriad) - Onxeo/Monopar Therapeutics
    7.4 Bone Metastases
    7.4.1 Bone Metastases Phase II and III Pipeline Overview
    7.4.2 Tanezumab - Pfizer and Eli Lilly
    7.5 Chemotherapy-Induced Neutropenia
    7.5.1 CIN Phase II and III Pipeline Overview
    7.5.2 Rolontis (eflapegrastim/SPI-2012) - Spectrum Pharmaceuticals and Hanmi Pharmaceuticals
    7.5.3 Plinabulin (NPI-2358) - BeyondSpring Pharmaceuticals
    7.6 Chemotherapy-Induced Anemia
    7.6.1 CIA Phase II and III Pipeline Overview
    7.6.2 SPP-003 (5-Aminolevulinic Acid Hydrochloride and Sodium Ferrous Citrate) - SBI Pharmaceuticals
    8 Unmet Needs and Opportunities
    8.1 Chemotherapy-Induced Nausea and Vomiting
    8.1.1 Therapies with More Effective Control of Nausea
    8.1.2 Novel Mechanisms of Action and Differentiation from Currently Available Therapies
    8.1.3 CINV Treatment/Regimens for Oral Anti-Cancer Drugs
    8.1.4 Education of Stakeholders on Available Treatment Options and Proper Utilization
    8.1.5 Other Unmet Needs
    8.2 Cancer Cachexia
    8.2.1 Huge Unmet Need for Treatments
    8.2.2 Need for Improved Diagnosis and Identification of Cachexia in Obese Patients
    8.2.3 Lack of Research, and Cachexia Not Given Priority in Cancer Care
    8.3 Oral Mucositis
    8.3.1 Need for Effective Treatments
    8.3.2 Improved Forms of Administration
    8.4 Bone Metastases
    8.4.1 New Targets and Novel Mechanisms of Action
    8.4.2 Improvements in Quality of Life and in Pain
    8.4.3 Therapies with Oral Administration
    8.4.4 Further Investigation of Corticosteroids for Painful Bone Metastases
    8.5 Chemotherapy-Induced Neutropenia
    8.5.1 New Treatments to Update Regimens from the Decades-Old Therapies Currently Available
    8.5.2 New Forms of Administration, Fewer Side Effects, and Biomarkers
    8.6 Chemotherapy-Induced Anemia
    8.6.1 Therapies with a Better Side Effect Profile and Faster Demonstration of Effectiveness than ESAs
    8.6.2 Further Investigation of IV Iron in CIA, and Subsequent Update to Treatment Guidelines
    9 R&D Strategies and Clinical Trial Design
    9.1 Overview of Clinical Development in Supportive Oncology
    9.2 Chemotherapy-Induced Nausea and Vomiting
    9.2.1 R&D Strategies
    9.2.2 Clinical Trial Design Considerations
    9.3 Cancer Cachexia
    9.3.1 R&D Strategies
    9.3.2 Clinical Trial Design Considerations
    9.4 Oral Mucositis
    9.4.1 R&D Strategies
    9.4.2 Clinical Trial Considerations
    9.5 Bone Metastasis
    9.5.1 R&D Strategies and Clinical Trial Considerations
    9.6 Chemotherapy-Induced Neutropenia
    9.6.1 R&D Strategies
    9.6.2 Clinical Trial Design Considerations
    9.7 Chemotherapy-Induced Anemia
    9.7.1 R&D Strategies and Clinical Trial Design Considerations
    10 Appendix
    10.1 Bibliography
    10.2 Abbreviations
    10.3 Primary Research - KOLs Interviewed for This Report
    10.4 About the Authors
    10.4.1 Analyst
    10.4.2 Therapy Area Director
    10.4.3 Epidemiologists
    10.4.4 Reviewers
    10.4.5 Global Director of Therapy Analysis and Epidemiology
    10.4.6 Global Head and EVP of Healthcare Operations and Strategy
    10.5 About GlobalData
    10.6 Contact Us
    10.7 Disclaimer
    1.1 List of Tables
    Table 1: 7MM, Diagnosed Incident Cases of All Cancer, Men and Women, Ages ≥20 Years
    Table 2: CINV Marketed Products Overview
    Table 3: Types of CINV
    Table 4: Product Profile - Emend
    Table 5: Product Profile - Emend for Injection / IVemend
    Table 6: Product Profile - Varubi and Varubi IV
    Table 7: Product Profile - Aloxi
    Table 8: Product Profile - Sustol
    Table 9: Product Profile - Akynzeo
    Table 10: Product Profile - Kepivance
    Table 11: Bone Metastases Marketed Products Overview
    Table 12: Product Profile - Xgeva
    Table 13: Product Profile - Xofigo
    Table 14: Product Profile - Zometa
    Table 15: Product Profile - Aredia
    Table 16: CIN Marketed Products Overview
    Table 17: Product Profile - Neupogen
    Table 18: Filgrastim Biosimilars
    Table 19: Product Profile - Granix
    Table 20: Product Profile - Granocyte
    Table 21: Product Profile - Neulasta
    Table 22: Product Profile - Lonquex
    Table 23: Product Profile - Leukine
    Table 24: CIA Marketed Products Overview
    Table 25: National Cancer Institute Anemia Scale
    Table 26: Product Profile - Procrit/Eprex/Epogen
    Table 27: Epoetin Alfa Biosimilars
    Table 28: Product Profile - NeoRecormon
    Table 29: Product Profile - Eporatio/Biopoin
    Table 30: Product Profile - Aranesp
    Table 31: CINV Phase II and III Pipeline
    Table 32: APD403 (Amisulpride) - Acacia Pharma, SWOT Analysis, 2017
    Table 33: Cinvanti (Aprepitant/HTX-019) - Heron Therapeutics, SWOT Analysis, 2017
    Table 34: Cancer Cachexia Phase II and III Pipeline
    Table 35: Adlumiz (Anamorelin) - Helsinn, SWOT Analysis, 2017
    Table 36: Xilonix (MABp1) - XBiotech, SWOT Analysis, 2017
    Table 37: Oral Mucositis Phase II and III Pipeline
    Table 38: Phase III Clinical Development Programs for SGX942 (Dusquetide) in Oral Mucositis
    Table 39: SGX942 (Dusquetide) - Soligenix, SWOT Analysis, 2017
    Table 40: Validive (Clonidine Lauriad) - Onxeo / Monopar Therapeutics, SWOT Analysis, 2017
    Table 41: Bone Metastases Phase II and III Pipeline
    Table 42: Phase III Clinical Development Programs for Tanezumab - Pfizer and Eli Lilly in Bone Metastases
    Table 43: Tanezumab - Pfizer and Eli Lilly, SWOT Analysis, 2017
    Table 44: CIN Phase II and III Pipeline
    Table 45: Phase III Clinical Development Program for Rolontis (Eflapegrastim/SPI-2012 - Spectrum Pharmaceuticals and Hanmi Pharmaceuticals) in CIN
    Table 46: Rolontis (Eflapegrastim/SPI-2012) - Spectrum Pharmaceuticals and Hanmi Pharmaceuticals, SWOT Analysis, 2017
    Table 47: Phase II/III Clinical Development Programs for Plinabulin (NPI-2358) - BeyondSpring Pharmaceuticals in CIN
    Table 48: Plinabulin (NPI-2358) - BeyondSpring Pharmaceuticals, SWOT Analysis, 2017
    Table 49: CIA Phase II and III Pipeline
    Table 50: SPP-003 (5-Aminolevulinic Acid Hydrochloride and Sodium Ferrous Citrate) - SBI Pharmaceuticals, SWOT Analysis, 2017
    Table 51: Oral Mucositis Pipeline Agents: Methods of Administration
    Table 52: Definitions of the Most Common CINV Trial Endpoints
    Table 53: Oral Mucositis Late-Stage Pipeline Agents: FDA Fast Track Designations
    Table 54: Primary Endpoints Used in Trials for Oral Mucositis Pipeline Agents
    Table 55: Examples of Primary and Secondary Endpoints that Can Be Studied in CIN Trials
    Table 56: Common Outcomes of Interest in Anemia Clinical Trials
    1.2 List of Figures
    Figure 1: 7MM, Age-Standardized Diagnosed Incidence of All Cancer, Men, Ages ≥18 Years, 2016-2026
    Figure 2: 7MM, Age-Standardized Diagnosed Incidence of All Cancer, Women, Ages ≥18 Years, 2016-2026
    Figure 3: 7MM, Sources Used to Forecast Diagnosed Incident Cases of All Cancer
    Figure 4: 7MM, Sources Used to Forecast Five-Year Diagnosed Prevalent Cases of All Cancer
    Figure 5: 7MM, Sources Used to Forecast Diagnosed Incident Cases of Prostate Cancer
    Figure 6: 7MM, Sources Used to Forecast Diagnosed Incident Cases of Breast Cancer
    Figure 7: 7MM, Sources Used to Forecast Diagnosed Incident Cases of Lung Cancer
    Figure 8: 7MM, Sources Used to Forecast Chemotherapy-Induced Conditions
    Figure 9: 7MM, Sources Used to Forecast Bone Metastasis in Prostate, Breast, and Lung Cancer
    Figure 10: 7MM, Diagnosed Incident Cases of All Cancer Receiving Chemotherapy Treatment, Men and Women, Ages ≥18 Years
    Figure 11: 7MM, Diagnosed Incident Cases of All Cancer With Chemotherapy-Induced Conditions, Men and Women, Ages ≥18 Years
    Figure 12: 7MM, Diagnosed Incident Cases of Prostate Cancer, Men, Ages ≥35 Years
    Figure 13: 7MM, Diagnosed Incident Cases of Prostate Cancer That Have Developed or Will Develop Bone Metastasis, Men, Ages ≥35 Years
    Figure 14: 7MM, Diagnosed Incident Cases of Breast Cancer, Women, Ages ≥20 Years
    Figure 15: 7MM, Diagnosed Incident Cases of Breast Cancer That Have Developed or Will Develop Bone Metastasis, Women, Ages ≥20 Years
    Figure 16: 7MM, Diagnosed Incident Cases of Lung Cancer, Men and Women, Ages ≥20 Years
    Figure 17: 7MM, Diagnosed Incident Cases of Lung Cancer That Have Developed or Will Develop Bone Metastasis, Men and Women, Ages ≥20 Years
    Figure 18: 7MM, Five-Year Diagnosed Prevalent Cases of All Cancer, Men and Women, All Ages
    Figure 19: Unmet Needs and Opportunities in CINV, 2017
    Figure 20: Unmet Needs and Opportunities in Cancer Cachexia, 2017
    Figure 21: Unmet Needs and Opportunities in Oral Mucositis 2017
    Figure 22: Unmet Needs and Opportunities in Bone Metastases, 2017
    Figure 23: Unmet Needs and Opportunities in CIN, 2017
    Figure 24: Unmet Needs and Opportunities in CIA 2017

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report